传统合成改善病情抗风湿药治疗类风湿关节炎窗口期对10年结局的积极影响:ESPOIR队列研究结果
基于ESPOIR队列418例10年DAS28和HAQ完整数据的类风湿关节炎患者及343例基线至10年影像学完整数据患者,评估改善病情抗风湿药对10年结局的影响。加权累积暴露模型预测性能最佳,FavOut的AUC为0.80(95%CI 0.74至0.87),AbsSDP的AUC为0.87(95%CI 0.83至0.92)。与基线即启动csDMARD相比,12个月时启动csDMARD者FavOut的OR为0.78(95%CI 0.65至0.94)、AbsSDP的OR为0.89(95%CI 0.76至0.98)。
要点
- 418例中196/418(46.9%)达FavOut,343例中252/343(73.5%)达AbsSDP。
- 12个月时启动csDMARD较基线启动者FavOut的OR 0.78(95%CI 0.65至0.94)。
- 12个月时启动csDMARD较基线启动者AbsSDP的OR 0.89(95%CI 0.76至0.98)。
核心结论
- 加权累积暴露模型可识别并量化早期启动csDMARD对类风湿关节炎患者10年功能与结构结局的长期获益。
研究设计与样本
- ESPOIR队列中10年DAS28与HAQ数据完整的类风湿关节炎患者418例,以及基线与10年影像学数据完整的患者343例。
- 构建三个多变量logistic回归模型预测10年结局:仅基线变量、基线变量加DMARD暴露(曾暴露是/否)、基线变量加DMARD暴露作为加权累积暴露变量。
主要发现
- 418例中196/418(46.9%)达FavOut,343例中252/343(73.5%)达AbsSDP。
- 加权累积暴露模型预测性能最佳,FavOut的AUC为0.80(95%CI 0.74至0.87),AbsSDP的AUC为0.87(95%CI 0.83至0.92)。
- 加权累积暴露模型中,12个月时启动csDMARD较基线启动者FavOut的OR为0.78(95%CI 0.65至0.94),AbsSDP的OR为0.89(95%CI 0.76至0.98)。
- 早期启动生物制剂与任一结局均无显著关联。
关键数值与推荐
- FavOut定义为10年时DAS28<2.6且HAQ评分<0.5。
- AbsSDP定义为10年时Sharp-van der Heijde评分变化小于最小可检测变化(11.5分)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: This study aimed to assess the impact of disease-modifying antirheumatic drugs (DMARDs) on 10-year outcomes in rheumatoid arthritis (RA). METHODS: Patients with RA from the ESPOIR cohort with complete data on Disease Activity Score in 28 Joints (DAS28) and Health Assessment Questionnaire (HAQ) at 10 years (n=418) and complete radiographic data at baseline and 10 years (n=343) were included in this study. Outcomes were favourable outcome (FavOut) at 10 years, defined as DAS28 of <2.6 and HAQ score of <0.5 at 10 years, and absence of structural damage progression (AbsSDP) at 10 years, defined as change in Sharp-van der Heijde Score less than the smallest detectable change at 10 years (11.5 points). Three multivariate logistic regression models predicting 10-year outcome were built, considering (1) baseline variables only, (2) baseline variables and DMARD exposure (ever exposed, yes/no) and (3) baseline variables and DMARD exposure as weighted cumulative exposure (WCE) variables. RESULTS: Overall, 196/418 (46.9%) patients showed FavOut and 252/343 (73.5%) AbsSDP. WCE models had the best predictive performance, with area under the curve=0.80 (95% CI 0.74 to 0.87) for FavOut and 0.87 (95% CI 0.83 to 0.92) for AbsSDP. In the WCE model, the odds of FavOut and AbsSDP were reduced with conventional synthetic disease-modifying antirheumatic drug (csDMARD) initiation at 12 months versus at baseline (OR 0.78, 95% CI 0.65 to 0.94, and OR 0.89, 95% CI 0.76 to 0.98, respectively). Early biologics initiation was not significantly associated with either outcome. CONCLUSIONS: WCE models can identify and quantify the long-term benefit of early csDMARD initiation on 10-year functional and structural outcomes in patients with RA.
引用
- Kedra J, Lafourcade A, Combe B, et al. Positive impact on 10-year outcome of the window of opportunity for conventional synthetic DMARDs in rheumatoid arthritis: results from the ESPOIR cohort. RMD Open. 2022. PMID: 35534053. doi:10.1136/rmdopen-2021-002040
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。